Skip to main content

Table 3 Effect of baseline covariates on hepatotoxicity in cohort (including HIV infection and hematologic malignancy, n = 1,007)

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Covariate * Covariate present Covariate absent P value Ϯ
  Treatment episodes Hepatotoxic episodes (%) Treatment episodes Hepatotoxic episodes (%)  
Hepatitis C§ 158 8(5.1) 849 26(3.1) 0.201
HIV infection§ 25 4(16.0) 982 30(3.1) 0.008
Hematologic malignancy§ 23 4(17.4) 984 30(3.1) 0.006
HBV antiviral prescription 29 5(17.2) 978 29(3.0) 0.002
Oral glucocorticoid prescription 364 19(5.2) 643 15(2.3) 0.015
Statin prescription 364 11(3.0) 643 23(3.6) 0.64
  1. *Defined within 12 months of index date unless otherwise specified; Ϯchi-square or Fisher’s exact test; §defined by International Classification of Diseases, Ninth Revision (ICD-9) codes 070.41, 070.44, 070.51, V0262 (hepatitis C), 042.XX (HIV infection), 200–208.92 (hematologic malignancy); prescription within six months of index date. HIV, human immunodeficiency virus.